Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Public ClinicalTrials.gov record NCT00005847. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase II Trial of Mitoxantrone, Estramustine and Navelbine or 13-cis Retinoic Acid, Interferon and Paclitaxel in Patients With Metatstatic Hormone Refractory Prostate Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. It is not yet known which treatment regimen is more effective in treating metastatic prostate cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of combination chemotherapy with that of chemotherapy plus biological therapy in treating patients who have progressive or metastatic prostate cancer that has not responded to hormone therapy.
Study identification
- NCT ID
- NCT00005847
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- recombinant interferon alfa Biological
- estramustine phosphate sodium Drug
- isotretinoin Drug
- mitoxantrone hydrochloride Drug
- paclitaxel Drug
- vinorelbine ditartrate Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years to 120 Years
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 5, 2001 (Actual)
- Primary completion
- Jul 2004 (Actual)
- Completion
- Not listed
- Last update posted
- Jun 22, 2023
Started 2001
United States locations
- U.S. sites
- 19
- U.S. states
- 13
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| CCOP - Colorado Cancer Research Program, Incorporated | Denver | Colorado | 80224 | — |
| Emory University Hospital - Atlanta | Atlanta | Georgia | 30322 | — |
| Veterans Affairs Medical Center - Atlanta (Decatur) | Decatur | Georgia | 30033 | — |
| CCOP - Carle Cancer Center | Urbana | Illinois | 61801 | — |
| Tufts - New England Medical Center | Boston | Massachusetts | 02111 | — |
| CCOP - Kalamazoo | Kalamazoo | Michigan | 49007-3731 | — |
| Mayo Clinic Cancer Center | Rochester | Minnesota | 55905 | — |
| CCOP - Metro-Minnesota | Saint Louis Park | Minnesota | 55416 | — |
| CCOP - Northern New Jersey | Hackensack | New Jersey | 07601 | — |
| Cancer Institute of New Jersey | New Brunswick | New Jersey | 08903 | — |
| MBCCOP-Our Lady of Mercy Cancer Center | The Bronx | New York | 10466 | — |
| CCOP - Merit Care Hospital | Fargo | North Dakota | 58122 | — |
| Ireland Cancer Center | Cleveland | Ohio | 44106-5065 | — |
| CCOP - Toledo Community Hospital | Toledo | Ohio | 43623-3456 | — |
| CCOP - Geisinger Clinic and Medical Center | Danville | Pennsylvania | 17822-2001 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| CCOP - Sioux Community Cancer Consortium | Sioux Falls | South Dakota | 57104 | — |
| CCOP - St. Vincent Hospital Cancer Center, Green Bay | Green Bay | Wisconsin | 54307-3453 | — |
| Medical College of Wisconsin Cancer Center | Milwaukee | Wisconsin | 53226-3596 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00005847, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 22, 2023 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00005847 live on ClinicalTrials.gov.